Drugs / RSVPreF3 vaccine
last change Jan 2025 re-read 2 minutes ago

RSVPreF3 vaccine

Vaccine

Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05705440 Feb 2023 → Jan 2025 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RSVPreF3 vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05705440
Modality Vaccine “RSVPreF3 vaccineNCT05705440